| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Some treatments not mentioned here (e.g. pacing, fluids, immunoglobulins) and for symptom-specific targeting: ↓↓↓ | Discussion: reddit.com/r/cfs reddit.com/r/covidlonghaulers forums.phoenixrising.me | Study results & comments → | |||||||||||||||||||||||
2 | CFS treatments (survey 2024) (vid) | CFS/LC research (2023) | CS = Case Series | LC = Long Covid, CFS=Chronic Fatigue Syndrome, FM=Fibromyalgia | ||||||||||||||||||||||
3 | Treatment recs (clinical coalition 2021) | LC treatments (2022) | RS = Retrospective Study, DBDT = Double Blind Discontinuation Trial, OS = Observational Study, RCT = Randomized Controlled Trial, CT = Controlled Trial | |||||||||||||||||||||||
4 | Class | Drug | Cost | Why? | Year | Study type | n | Study (group + link) | Dosage & test period | Result (P/N) | Exact result | Notes | Pro (anecdotal) | Contra (anecdotal) | ||||||||||||
5 | antihistamine | antihistamines (H1 & H2 blockers) | mast cell activation (MCA) symptoms widely present in LC [1] | 2023 | RS (controlled) | 27 | LC | (fexofenadine 180mg, famotidine 40mg) 20d | P | 29%: all symptoms disappeared, significant improvement in rest; responder %: {fatigue↓: 64%, brain fog↓: 27%, increased HR↓: 56%, abdominal disorders: 48%} | A study criteria: "no registered benefits from previous treatment for long-COVID" | top voted in Long Covid Care group re:brain fog; re: MCAS, success stories, 2; for many 1 didn't work, other did | ||||||||||||||
6 | antihistamines (H1 & H2 blockers) | 2021 | OS (controlled) | 49 | LC | 2 x (loratadine 10mg or fexofenadine 180 mg)/d and 1 x (famotidine 40 mg or nizatidine 300 mg)/d 30d (6-89d) | P | symptom severity: 26%↓ (disappeared in: {fatigue: 29%, PEM: 0%, neurologic: 52%, dysautonomia: 0%, chest pain: 37%, ...}) | Gen1 anti-H1-s cross brain-blood barrier, but have more side effects | |||||||||||||||||
7 | nattokinase | microclot breakdown [1], COVID-19 virus' spike protein breakdown [2] | 2024 | survey | CFS/LC | 8k FUs needed to take effect; if possible use enteric coating (some say it works fine without) | P | improvement in 60% (brain fog, fatigue, PEM) | 1 [LC brain fog]; also good for Alzheimer management | worsening fatigue [1 LC, herxing?]; if side effects don't go away (4 weeks?) try lumbrokinase instead (not fermented, no histamine) | ||||||||||||||||
8 | immunomodulator | low dose naltrexone (LDN) | anti-inflammatory | 2019 | OS | 218 | CFS | (3 - 4.5mg on evenings) 1.7y (if insomnia, in mornings) | P | 51%: improved vigilance, 24%: physical performance↑, 21%: cognitive dysfunction diminished | LC: helped [brain fog], CFS: 2 [side effect: "poisoned"], many positive benefits [e.g. 20% impr. brain fog, PEM improvement] side effects: stomach] | (CFS: made depression worse to psychosis) | ||||||||||||||
9 | immunomodulator | low dose naltrexone (LDN) | 2014 | review | chronic pain & inflammatory | P | ||||||||||||||||||||
10 | antipsychotic | low dose aripiprazole | D2 receptor: mediate neuroinflammation, microglial activation, and cell death [1] | 2021 | RS | 101 | CFS | 1.1mg (0.2-2mg) (titrated up by 0.25mg) 8m (1m-17m) | P | 74%: [45%↓ severity in fatigue, brain fog & unrefreshing sleep; imrovement in PEM crashes] | 1 [long covid brain fog] | |||||||||||||||
11 | nAChRs agonist | nicotine | stimulant | 2023 | CS | 4 | LC | 7-15mg 6-7d [if too large put tape under x% of it, or cut it] | P | resolved fatigue, concentration issues, ... | article | effects short duration? (tolerance); possibly fake energy, giving you PEM | ||||||||||||||
12 | alpha-2a agonist | guanfacine | $40/m | strengthens prefrontal connectivity [1]; POTS relief [2] | 2023 | CS | 12 | LC: w/ NAC | 1mg guanfacine (XR) for 1 month @bedtime, then 2mg (NAC: 600mg) | P | reduction in brain fog (if guanfacine tolerated) | clonidine is a same group drug, but more sedating. also recommended for POTS | helped some [bad recall & word finding; improved aft. 2w, significantly aft. 7.5M; ], 2 [with 5-10 sec memory; con: for him NAC helped too], 3 [elo ratings improved; didn't help with fatigue?], others: helped with PEM (after 6M), with flight&fight adrenaline shots; 4 [brainfog stimuli related], | fatigue (for at least 1-2 weeks); low BP; usually improves executive function, but sometimes the opposite (paranoia, anger); usually taken for anxiety and sleep? (sometimes alongside stimulants for calming effect); overall the effectiveness rate in r/covidlonghaulers for brain fog was like 50% (weirdly in r/ADHD it was lower!), although many stopped taking due to the initial fatigue; helped more with brain fog than fatigue | ||||||||||||
13 | antioxidant | N-acetylcysteine (NAC) | protects mitochondria and reduces kynurenic acid blockade of NMDA receptors [1] [2] | 2023 | CS | 12 | LC: w/ guanfacine | 600mg NAC (1mg guanfacine (XR) for 1 month @bedtime, then 2mg) | P | reduction in brain fog (if guanfacine tolerated) | in r/covidlonghaulers the effectiveness was mild and ~30%; for some it made worse | |||||||||||||||
14 | oxaloacetate | $330/m @1000mg | brain mitochondrial biogenesis, insulin pathway, hippocampal neurogenesis [1] | 2022 | RCT | 120 | CFS | 1000-3000mg 2-(6)w (Anhydrous Enol-Oxaloacetate (AEO)) | P | physical fatigue 16-29%↓, mental fatigue 13-26%↓ | 1 [LC] | |||||||||||||||
15 | MitoQ/CoQ10 | mitochondrial oxidative phosphorylation process | 2024 | review | 750 | FM/CFS | Q10: ~300mg 40d-3m | P | 12/13 studies showed improvement | CoQ10 (ubiquinone), i.e. the oxidized form | ||||||||||||||||
16 | MitoQ/CoQ10 | 2020 | OS | 20 | middle-aged men | (MitoQ: 20mg, Q10: 200mg) 6w | N | no effect on mitochondria (besides mildly suppressing ROS levels (MitoQ more effective than Q10)) | ||||||||||||||||||
17 | NADH | ATP production↑, dopamine↑ [1] | 2004 | RCT | 31 | CFS | 5-10mg 2y | P? | symptom score 50%↓, but as good as therapy group | |||||||||||||||||
18 | NADH | 2021 | RCT | 242 | CFS: w/ CoQ10 | (Q10: 200mg, NADH: 20mg) 12w | N | no significant improvement | ||||||||||||||||||
19 | ...other NAD+ related: NMN (nicotinamide mononucleotide) & nicotinamide riboside | | ||||||||||||||||||||||||
20 | alpha-lipoic acid (ALA) | mitochondrial α-ketoacid dehydrogenases, glutathione levels [1] | 2022 | RCT | 174 | CFS: w/ CoQ10 | 2 x (Q10 100mg + ALA 100mg)/d 8w; 300-2400mg (in diabetic neuropathy / MS patients) | P | VAS: (fatigue 35%↓, pain 50%↓, sleep 41%↓) | |||||||||||||||||
21 | (acetyl) L-carnitine (ALCAR) | fatty acids transport into mitochondria [1] | 1997 | OS | 14 | CFS | (3 x 1g)/d 4-8w | P | depression↓, anxiety↓, OCD↓, paranoia↓, ...↓ | |||||||||||||||||
22 | (acetyl) L-carnitine (ALCAR) | 2000 | RCT | 50 | CFS: blood levels | N | no lowered L-carnitive levels in CFS patients | |||||||||||||||||||
23 | palmitoylehanolamide (PEA) | restores GABA-B neurotransmission and cortical plasticity, olfactory function [1]; MCA down-regulation [2] | 2024 | survey | CFS/LC | P | improvement in 48% (fatigue & brain fog) | |||||||||||||||||||
24 | beta blockers | POTS relief | 2024 | survey | CFS/LC | P | improvement in 70% (POTS) | |||||||||||||||||||
25 | amifampridine | $650/m @10mg | reduces fatigue in multiple sclerosis patients | 2024 | DBDT | 5 | LC | 5-20mg, 3d test period | P | sleep time↓ 12-17h→8h; Bell score↑10-40→40-100 | alternative drug: fampridine | |||||||||||||||
26 | AChE inhibitor | pyridostigmine (Mestinon) | POTS relief [1]; dysautonomia relief (gut motility) [2] | 2024 | survey | CFS/LC | P | improvement in 60% (mostly POTS; also: fatigue, PEM, brain fog) | ||||||||||||||||||
27 | antiviral | maraviroc | 2024 | survey | CFS/LC | P | improvement in 65% | |||||||||||||||||||
28 | NDRI | methylphenidate | stimulant | 2016 | DBRCT | 194 | CFS | 4w | P | 17%: fatigue >50%↓, 22%: concentration issues >50%↓ (65% had stopped the treatment, they're counted as negative) | ||||||||||||||||
29 | NDRI | methylphenidate | 2006 | DBRCT | 60 | CFS | (2 x 10mg)/d | P | VAS fatigue: 13%↓ | |||||||||||||||||
30 | ||||||||||||||||||||||||||
31 | POTS = postural orthostatic tachycardia syndrome | "51%: improved vigilance" means that vigilance improved in 51% cases "VAS fatigue:13%↓" means fatigue severity dropped 13% more than in control (if controlled study) | ||||||||||||||||||||||||
32 | ||||||||||||||||||||||||||
33 | ||||||||||||||||||||||||||
34 | ||||||||||||||||||||||||||
35 | ||||||||||||||||||||||||||
36 | ||||||||||||||||||||||||||
37 | ||||||||||||||||||||||||||
38 | ||||||||||||||||||||||||||
39 | ||||||||||||||||||||||||||
40 | ||||||||||||||||||||||||||
41 | ||||||||||||||||||||||||||
42 | ||||||||||||||||||||||||||
43 | ||||||||||||||||||||||||||
44 | ||||||||||||||||||||||||||
45 | ||||||||||||||||||||||||||
46 | ||||||||||||||||||||||||||
47 | ||||||||||||||||||||||||||
48 | ||||||||||||||||||||||||||
49 | ||||||||||||||||||||||||||
50 | ||||||||||||||||||||||||||
51 | ||||||||||||||||||||||||||
52 | ||||||||||||||||||||||||||
53 | ||||||||||||||||||||||||||
54 | ||||||||||||||||||||||||||
55 | ||||||||||||||||||||||||||
56 | ||||||||||||||||||||||||||
57 | ||||||||||||||||||||||||||
58 | ||||||||||||||||||||||||||
59 | ||||||||||||||||||||||||||
60 | ||||||||||||||||||||||||||
61 | ||||||||||||||||||||||||||
62 | ||||||||||||||||||||||||||
63 | ||||||||||||||||||||||||||
64 | ||||||||||||||||||||||||||
65 | ||||||||||||||||||||||||||
66 | ||||||||||||||||||||||||||
67 | ||||||||||||||||||||||||||
68 | ||||||||||||||||||||||||||
69 | ||||||||||||||||||||||||||
70 | ||||||||||||||||||||||||||
71 | ||||||||||||||||||||||||||
72 | ||||||||||||||||||||||||||
73 | ||||||||||||||||||||||||||
74 | ||||||||||||||||||||||||||
75 | ||||||||||||||||||||||||||
76 | ||||||||||||||||||||||||||
77 | ||||||||||||||||||||||||||
78 | ||||||||||||||||||||||||||
79 | ||||||||||||||||||||||||||
80 | ||||||||||||||||||||||||||
81 | ||||||||||||||||||||||||||
82 | ||||||||||||||||||||||||||
83 | ||||||||||||||||||||||||||
84 | ||||||||||||||||||||||||||
85 | ||||||||||||||||||||||||||
86 | ||||||||||||||||||||||||||
87 | ||||||||||||||||||||||||||
88 | ||||||||||||||||||||||||||
89 | ||||||||||||||||||||||||||
90 | ||||||||||||||||||||||||||
91 | ||||||||||||||||||||||||||
92 | ||||||||||||||||||||||||||
93 | ||||||||||||||||||||||||||
94 | ||||||||||||||||||||||||||
95 | ||||||||||||||||||||||||||
96 | ||||||||||||||||||||||||||
97 | ||||||||||||||||||||||||||
98 | ||||||||||||||||||||||||||
99 | ||||||||||||||||||||||||||
100 |